Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jun 12;109(2):413-419.
doi: 10.4269/ajtmh.23-0091. Print 2023 Aug 2.

Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation

Affiliations

Previous Dengue Infection among Children in Puerto Rico and Implications for Dengue Vaccine Implementation

Laura E Adams et al. Am J Trop Med Hyg. .

Abstract

Limited dengue virus (DENV) seroprevalence estimates are available for Puerto Rico, which are needed to inform the potential use and cost-effectiveness of DENV vaccines. The Communities Organized to Prevent Arboviruses (COPA) is a cohort study initiated in 2018 in Ponce, Puerto Rico, to assess arboviral disease risk and provide a platform to evaluate interventions. We recruited participants from households in 38 study clusters, who were interviewed and provided a serum specimen. Specimens from 713 children aged 1 to 16 years during the first year of COPA were tested for the four DENV serotypes and ZIKV using a focus reduction neutralization assay. We assessed the seroprevalence of DENV and ZIKV by age and developed a catalytic model from seroprevalence and dengue surveillance data to estimate the force of infection for DENV during 2003-2018. Overall, 37% (n = 267) were seropositive for DENV; seroprevalence was 9% (11/128) among children aged 1 to 8 years and 44% (256/585) among children aged 9 to 16 years, exceeding the threshold over which DENV vaccination is deemed cost-effective. A total of 33% were seropositive for ZIKV, including 15% among children aged 0 to 8 years and 37% among children aged 9 to 16 years. The highest force of infection occurred in 2007, 2010, and 2012-2013, with low levels of transmission from 2016 to 2018. A higher proportion of children had evidence of multitypic DENV infection than expected, suggesting high heterogeneity in DENV risk in this setting.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Estimated dengue seroprevalence by age among children aged 1 to 16 years in Ponce, Puerto Rico, 2018–2019 (A) and estimated proportion with one and multiple previous infections (B). Open circles represent the proportion of participants seropositive to dengue virus. In panel A, colors represent the seroprevalence data (black) and fits to the serosurvey data (gray), the case data (blue), and both data together (red). In panel B, red lines represent the fit from the serosurvey and case data together.
Figure 2.
Figure 2.
Proportion of dengue virus–seropositive individuals in Ponce, Puerto Rico, 2018–2019 with evidence for multiple previous infections, among individuals with and without evidence for prior Zika infection. Points and vertical lines represent observed proportions and 95% CIs, whereas solid black line and gray ribbon represent model-estimated median proportions and 95% credible intervals, respectively. Where 95% CIs around the observed proportions are not shown, they are undefined due to zero counts of monotypic or multitypic infections.

Similar articles

Cited by

References

    1. Bhatt S. et al., 2013. The global distribution and burden of dengue. Nature 496: 504–507. - PMC - PubMed
    1. Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G, Gordon A, Balmaseda A, Harris E, 2017. Antibody-dependent enhancement of severe dengue disease in humans. Science 358: 929–932. - PMC - PubMed
    1. Paz-Bailey G, Adams L, Wong JM, Poehling KA, Chen WH, McNally V, Atmar RL, Waterman SH, 2021. Dengue vaccine: recommendations of the advisory committee on immunization practices, United States, 2021. MMWR Recomm Rep 70: 1. - PMC - PubMed
    1. Sridhar S. et al., 2018. Effect of dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med 379: 327–340. - PubMed
    1. Hadinegoro SR, Arredondo-García JL, Capeding MR, Deseda C, Chotpitayasunondh T, Dietze R, Hj Muhammad Ismail H, Reynales H, Limkittikul K, Rivera-Medina DM, 2015. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 373: 1195–1206. - PubMed

Publication types

LinkOut - more resources